12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Debio 0932: Phase I data

An open-label, dose-escalation, French Phase I trial in 51 evaluable patients with advanced solid tumors or lymphoma who were resistant to standard therapy showed that Debio 0932 given daily or every other day was generally well tolerated with no ocular or cardiac toxicity reported. Dose-limiting toxicities (DLTs) included febrile neutropenia at the once-daily 1,600 mg dose of...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >